Oragenics (NYSEAMERICAN:OGEN) Shares Up 1.5% – Still a Buy?

Oragenics, Inc. (NYSEAMERICAN:OGEN)’s share price rose 1.5% during trading on Tuesday . The company traded as high as $1.45 and last traded at $1.37. Approximately 219,614 shares changed hands during trading, a decline of 6% from the average daily volume of 233,063 shares. The stock had previously closed at $1.35.

Oragenics Stock Up 1.5%

The business has a 50 day moving average of $1.22 and a 200 day moving average of $2.91. The company has a market capitalization of $5.66 million, a P/E ratio of -0.06 and a beta of 0.83.

Institutional Investors Weigh In On Oragenics

A hedge fund recently raised its stake in Oragenics stock. Bank of America Corp DE raised its stake in shares of Oragenics, Inc. (NYSEAMERICAN:OGEN) by 7,374.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,546 shares of the company’s stock after purchasing an additional 15,338 shares during the period. Bank of America Corp DE owned 1.89% of Oragenics worth $59,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 18.71% of the stock is owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.